Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX35 and HLX10 in Advanced or Metastatic Solid Tumors
NCT05442996Phase 1Unknown
- Sponsor
- Henlius
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of HLX35 in solid tumor, sponsored by Henlius. Primary endpoints: Number of occurrences and incidence of each adverse event (AE) up to 2 years, The proportion of patients experiencing dose limiting toxicity (DLT) events and 1 more. Status: unknown.
02
Drugs
HLX35
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05442996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442996.